Skip to main content

Advertisement

SpringerLink
Log in

Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Harbell J, Terrault NA, Stock P (2013) Solid organ transplants in HIV-infected patients. Curr HIV/AIDS Rep 10:217–225

    Article  PubMed  Google Scholar 

  2. Sawinski D, Goldberg DS, Blumberg E, Abt PL, Bloom RD, Forde KA (2015) Beyond the NIH Multicenter HIV Transplant Trial experience: outcomes of HIV+ liver transplant recipients compared to HCV+ or HIV+/HCV+ coinfected recipients in the United States. Clin Infect Dis [Epub ahead of print]

  3. Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P et al (2011) Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS 25:777–786

    Article  PubMed  Google Scholar 

  4. Terrault NA (2005) Treatment of recurrent hepatitis C in liver transplant recipients. Clin Gastroenterol Hepatol 3(10 Suppl 2):S125–S231

    Article  CAS  PubMed  Google Scholar 

  5. Berenguer M (2002) Natural history of recurrent hepatitis C. Liver Transpl 8(10 Suppl 1):S14–S18

    Article  PubMed  Google Scholar 

  6. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C et al (2015) Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 313:1223–1231

    Article  CAS  PubMed  Google Scholar 

  7. Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C et al (2014) Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. J Int AIDS Soc 17(4 Suppl 3):19500

    PubMed Central  PubMed  Google Scholar 

  8. Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T et al (2015) Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 15:1313–1322

    Article  CAS  PubMed  Google Scholar 

  9. Waki K, Sugawara Y (2011) Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572). Biosci Trends 5:189–191

    Article  CAS  PubMed  Google Scholar 

  10. Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y et al (2009) Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 9:1946–1952

    Article  CAS  PubMed  Google Scholar 

  11. Cattaneo D, Ripamonti D, Gervasoni C, Landonio S, Meraviglia P, Baldelli S et al (2012) Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients. J Clin Pharmacol 52:440–445

    Article  CAS  PubMed  Google Scholar 

  12. Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC (2014) Long-term efficacy and safety of raltegravir in the management of HIV infection. Infect Drug Resist 7:73–84

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Barau C, Braun J, Vincent C, Haim-Boukobza S, Molina JM, Miailhes P et al (2014) Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study. Clin Infect Dis 59:1177–1184

    Article  PubMed  Google Scholar 

  14. Cianfriglia M, Dupuis ML, Molinari A, Verdoliva A, Costi R, Galluzzo CM et al (2007) HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 4:17–18

    Article  PubMed Central  PubMed  Google Scholar 

  15. Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H (2013) Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Biochem Biophys Res Commun 439:221–227

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was carried out as part of our routine work.

Transparency declarations

None to declare.

Compliance with ethical standards

This is a retrospective observation describing a case; the patient provided written consent for the case report.

Conflict of interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Unit of Clinical Pharmacology, L. Sacco University Hospital, Milan, Italy

    Dario Cattaneo & Nitin Charbe

  2. Department of Infectious Diseases, Luigi Sacco University Hospital, Via GB Grassi 74, 20157, Milan, Italy

    Salvatore Sollima, Chiara Resnati & Cristina Gervasoni

  3. Clinical Pharmacology Unit, CNR Institute of Neuroscience, Dept Biomedical and Clinical Sciences, L. Sacco University Hospital, Università di Milano, 20157, Milan, Italy

    Emilio Clementi

  4. Scientific Institute IRCCS E. Medea, 23842, Bosisio Parini, Italy

    Emilio Clementi

Authors
  1. Dario Cattaneo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salvatore Sollima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nitin Charbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiara Resnati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emilio Clementi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cristina Gervasoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristina Gervasoni.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cattaneo, D., Sollima, S., Charbe, N. et al. Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. Eur J Clin Pharmacol 72, 365–367 (2016). https://doi.org/10.1007/s00228-015-1936-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-015-1936-6

Keywords

Search

Navigation